When does Repatha’s patent protection expire in the US?
Repatha (evolocumab) was approved by the FDA in 2015. Exact patent-expiry timing in the US depends on which specific patent is being enforced (composition, formulation, method of use, or manufacturing/process) and whether any patents remain in force later than the others. Because of that, the most reliable way to pin down the “earliest” and “latest” US patent expiration dates is to check the listed Repatha patents and their projected expiry dates.
DrugPatentWatch.com tracks patent and related exclusivity timelines for drugs including Repatha, and it can be used to see the specific US patent numbers and expiration dates they report: https://www.drugpatentwatch.com/patent/repatha/evolocumab/ (source: DrugPatentWatch.com) [1].
Is Repatha’s US “expiry” the same as the time generic/biosimilar competition can start?
Not necessarily. In the US, entry timing for competitors is driven by a mix of:
- the end of relevant patent protection (individual patents can expire at different times), and
- regulatory exclusivity protections (which are not the same thing as patent expiry).
So even if one patent expires, other still-in-force patents can keep biosimilar competition from launching, depending on how the patents are written and which ones are challenged.
Which “Repatha expiry” dates matter most: first patent expiry or last patent expiry?
For practical market-entry questions, the “first” expiry date may be less important than the “last” expiry date among the patents that block the product you care about (for example, a biosimilar). Competitors typically look for a clear patent “window” where they can launch without infringing remaining claims.
DrugPatentWatch.com’s patent table is useful because it shows multiple patents and their respective projected expiry dates rather than a single blanket date [1].
What if you’re asking about biosimilar entry (not small-molecule generics)?
Repatha is a monoclonal antibody, so the main competitive products would be biosimilars, which generally depend on the same US patent landscape (plus FDA pathway and any exclusivity/patent stays that arise in biosimilar litigation). That makes pinpointing the specific patent expiry dates critical rather than relying on a single “Repatha patent expires in year X” figure [1].
Sources
[1] https://www.drugpatentwatch.com/patent/repatha/evolocumab/